Abstract library

6 results for "Michael".
#1073 The Clinical Oncology Society of Australia (COSA) SIGNETURe Neuroendocrine Tumor (NET) Registry of Australia: First Report of Patient Characteristics and Patterns of Care
Introduction: NETs remain a relatively rare malignancy. Clinical trials are often hindered by the limited number of patients available and thus registries provide important information about patterns of care and patient outcomes.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: A/Prof Timothy Price
Keywords: Registry
#1158 A Phase II Study of Everolimus in Patients with FDG-PET Positive Intermediate Grade (Ki67 3-20%) Pancreatic Neuroendocrine Tumor
Introduction: The RADIANT-3 trial showed Everolimus (EV), as active in patients (pts) with progressive well/intermediate grade PNETs. Intermediate/grade 2 (Ki67 3-20%) PNETs have variable biology. FDG-PET avidity is an independent negative factor for survival, consistent with aggressive disease biology- but such imaging is not used to select treatment as in the case of the RADIANT 3 trial.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: ASSOC PROF Michael Michael
Authors: Michael M, Pavlakis N, Wyld D, Link E, ...
Keywords: everolimus, FDG-PET
#1391 Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) - A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT)
Introduction: Bulky disease from NET is an adverse prognostic factor for response to 177Lu-DOTA-octreotate (LuTate) PRCRT. 90Y-DOTA-octreotate (YTate) has more penetrating particulate emissions.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Grace Kong
Keywords: PRRT, Y-90
#2178 Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumor: Preliminary Baseline Characteristics from the Nutrition in NETs Study
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP NET) cause various symptoms impacting on nutritional status and diet. Published data indicates up to 25% of GEP NET patients are malnourished, and dietary change is prevalent. Further research is required to guide nutrition recommendations.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Erin Kennedy
Authors: Kennedy E, Kiss N, Michael M, Gough K, ...
#2179 Exploring Nutrition Screening and Management Practices amongst Health Professionals Managing Patients with Neuroendocrine Tumors
Introduction: Patient’s with neuroendocrine tumours (NET) are at nutritional risk due to symptoms and side-effects of treatment. Current evidence based guidelines lack information regarding optimal nutritional management and supportive care.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Erin Kennedy
Authors: Kennedy E, Kiss N, Michael M, Gough K, ...
#2182 Favourable Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Metastatic Rectal Neuroendocrine Neoplasia (NEN)
Introduction: Metastatic disease from rectal NEN are less common than other NEN origins, and carries a poor prognosis. Treatment evidence for such patients (pts) is lacking.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Grace Kong